All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sylvester Researchers Help Identify Mechanisms by Which Multiple Myeloma Escapes Targeted Immunotherapy

September 4th 2023

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant to initially effective T-cell therapies.

Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future

September 4th 2023

James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.

PRGN-2009 Plus Bintrafusp Alfa Shows Early Activity in HPV-Associated Malignancies

September 3rd 2023

James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm.

Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in Advanced Nonsquamous NSCLC

September 1st 2023

Combination treatment with atezolizumab, carboplatin, and pemetrexed showed activity in patients with advanced nonsquamous non–small cell lung cancer and untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment.

Biomarker Analysis Contextualizes RFS Benefit With Nivolumab in Metastatic Melanoma

September 1st 2023

Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.

Momelotinib Could Represent Pivotal New Treatment Option in Myelofibrosis

September 1st 2023

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

Prolgolimab Combo Shows Antitumor Activity and Safety in Advanced Cervical Cancer

September 1st 2023

Administration of the anti–PD-1 antibody prolgolimab in combination with bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer.

Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

September 1st 2023

The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.

Sireesha Datla, MD Joins Florida Cancer Specialists & Research Institute

September 1st 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome hematologist and medical oncologist Sireesha Datla, MD to the statewide practice.

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

September 1st 2023

Adjuvant treatment with alectinib generated a statistically significant and clinically meaningful improvement in disease-free survival compared with platinum-based chemotherapy in patients with completely resected stage IB to IIIA, ALK-positive non–small cell lung cancer.

TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha and PD-1 Inhibition in HNSCC

September 1st 2023

Bernard Doger de Spéville, MD, PhD, discusses the investigation of eftilagimod alpha plus pembrolizumab in the TACTI-002 trial, including prior evidence supporting this approach, the trial’s design and primary objective, and the combination’s efficacy and safety in both the head and neck squamous cell carcinoma and non–small cell lung cancer cohorts.

Dendritic Cell Vaccines Represent Potential Avenue to Enhance Immunotherapy in Ovarian Cancer

September 1st 2023

Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

August 31st 2023

Mitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.

Perioperative Trials Add to Growing Immunotherapy Landscape in Early-Stage NSCLC

August 31st 2023

Emerging data continue to shape perioperative therapy decisions for patients with early-stage non–small cell lung cancer.

CAR T-Cell Therapy Innovations Unfold Across the Spectrum of Cancer Care

August 31st 2023

Martin E. Gutierrez, MD, and Lori A. Leslie, MD, discuss common barriers to implementing CAR T-cell therapy programs, early successes that John Theurer Cancer Center in New Jersey has seen with outpatient CAR T-cell therapy administration, and developments on the horizon for administering this approach in solid tumors

Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC

August 31st 2023

Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.

Tagraxofusp Receives Orphan Drug Designation in Japan for BPCDN

August 31st 2023

The Japanese Ministry of Health, Labor and Welfare has granted an orphan drug designation to tagraxofusp-erzs for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Fox Chase Social Worker Anjali Albanese to Receive 2023 Compassionate Care Award From Sarcoma Foundation of America

August 31st 2023

Anjali Albanese, MSW, LSW, OSW-C, a licensed social worker at Fox Chase Cancer Center, will receive the Compassionate Care Award from the Sarcoma Foundation of America during the Stand Up to Sarcoma Gala on September 19 in New York.

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023

The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.